{"disease":{"id":"cardiovascular-disease-and-lipoprotein-a","name":"cardiovascular disease and lipoprotein a"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03887520","title":"Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":49001,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04023552","title":"Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8323,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07517263","title":"An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5700,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}